This Soleno Therapeutics Insider Reduced Their Stake By 92%
This Soleno Therapeutics Insider Reduced Their Stake By 92%
Looking at Soleno Therapeutics, Inc.'s (NASDAQ:SLNO ) insider transactions over the last year, we can see that insiders were net sellers. That is, there were more number of shares sold by insiders than there were purchased.
看看 Soleno Therapeutics, Inc.”s(纳斯达克股票代码:SLNO)在过去一年的内幕交易中,我们可以看到内部人士是净卖家。也就是说,内部人士出售的股票数量多于购买的股票数量。
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
尽管我们认为股东不应简单地关注内幕交易,但我们确实认为密切关注内部人士的所作所为是完全合乎逻辑的。
Check out our latest analysis for Soleno Therapeutics
查看我们对 Soleno Therapeutics 的最新分析
Soleno Therapeutics Insider Transactions Over The Last Year
Soleno Therapeutics 过去一年的内幕交易
In the last twelve months, the biggest single sale by an insider was when the insider, Jack Schuler, sold US$474k worth of shares at a price of US$1.52 per share. So it's clear an insider wanted to take some cash off the table, even below the current price of US$21.93. As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. We note that the biggest single sale was 92% of Jack Schuler's holding. Jack Schuler was the only individual insider to sell shares in the last twelve months.
在过去的十二个月中,内部人士最大的一次出售是内部人士杰克·舒勒以每股1.52美元的价格出售了价值47.4万美元的股票。因此,很明显,一位内部人士想从牌桌上提取一些现金,甚至低于目前的21.93美元的价格。通常,当内部人士以低于当前价格的价格出售时,我们认为这会令人沮丧,因为这表明他们对较低的估值感到满意。尽管内幕抛售不是一个积极的信号,但我们无法确定这是否意味着内部人士认为股票已被充分估值,因此这只是一个弱势信号。我们注意到,最大的单笔销售额是杰克·舒勒持股的92%。杰克·舒勒是过去十二个月中唯一一位出售股票的个人内部人士。
You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
您可以在下面看到对过去 12 个月内幕交易(公司和个人)的直观描述。如果你点击图表,你可以看到所有的个人交易,包括股价、个人和日期!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231109/0-428ce28cd58cdbdecc14d0dde3d22f1a-0-e3541b725c348200055dd2651ff55efc.png/big)
I will like Soleno Therapeutics better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
如果我看到一些大规模的内幕买入,我会更喜欢 Soleno Therapeutics。在我们等待的同时,请查看这份免费名单,列出了最近有大量内幕买入的成长型公司。
Does Soleno Therapeutics Boast High Insider Ownership?
Soleno Therapeutics 是否拥有很高的内幕所有权?
For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. From our data, it seems that Soleno Therapeutics insiders own 1.1% of the company, worth about US$6.9m. Whilst better than nothing, we're not overly impressed by these holdings.
对于普通股股东来说,值得检查一下公司内部人士持有多少股票。我认为,如果内部人士拥有该公司的大量股份,那将是一个好兆头。从我们的数据来看,索理诺疗法内部人士似乎拥有该公司1.1%的股份,价值约690万美元。尽管总比没有好,但这些持股并没有给我们留下太深刻的印象。
So What Does This Data Suggest About Soleno Therapeutics Insiders?
那么,这些数据对索理诺治疗业内人士有何启示呢?
The fact that there have been no Soleno Therapeutics insider transactions recently certainly doesn't bother us. We don't take much encouragement from the transactions by Soleno Therapeutics insiders. We also note that, as far as we can see, insider ownership is fairly low, compared to other companies. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. At Simply Wall St, we found 3 warning signs for Soleno Therapeutics that deserve your attention before buying any shares.
最近索理诺疗法没有进行内幕交易这一事实当然不会打扰我们。Soleno Therapeutics内部人士的交易并没有给我们带来太大的鼓舞。我们还注意到,据我们所见,与其他公司相比,内部所有权相当低。虽然我们喜欢了解内部人士的所有权和交易情况,但在做出任何投资决定之前,我们也一定要考虑股票面临的风险。在Simply Wall St,我们发现了 Soleno Therapeutics 的三个警告信号,在购买任何股票之前,这些信号值得你注意。
Of course Soleno Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
当然,Soleno Therapeutics可能不是最值得买入的股票。因此,您可能希望看到这些免费的高质量公司集。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。